45 completed, 10 terminated, 7 recruiting, 4 withdrawn. 34 Phase 2, 22 Phase 3, 13 Phase 1, 6 Not applicable, 4 Phase 4.
Follow matched placebo: new trials by email Literature Review of matched placebo trials Research Report on matched placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multi-Component Nutrition, Intrinsic Capacity, and Physical Function in Older Adults Multi-Component Nutritional Formula, matched placebo - Sarcopenia, Intrinsic Capacity | Not applicable | Not yet recruiting | National Yang Ming Chiao Tung University | 70 | 2026-08-31 | 2026-09-11 |
| Tranexamic Acid for Anaemia Trial Tranexamic Acid 500 MG, Placebo - Anaemia | Phase 3 | Recruiting | London School of Hygiene and Tropical Medicine | 4000 | 2026-08-10 | 2026-08-17 |
| Preoperative Stapokibart for Endoscopic Sinus Surgery in Chronic Rhinosinusitis With Nasal Polyps Stapokibart, Matched placebo - Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Not applicable | Not yet recruiting | Beijing Tongren Hospital | 48 | 2026-06-01 | 2026-06-01 |
| To studyJUV-161 Administered to Healthy Volunteers Undergoing Unilateral Lower Limb Immobilization (ULLI) JUV-161, Placebo - Healthy Volunteers | Phase 1 / Phase 2 | Recruiting | Juvena Therapeutics | 36 | 2026-02-28 | 2026-04-20 |
| Glucokinase Activator in Monogenic Diabetes Dorzagliatin, matched placebo - Diabetes Mellitus, Monogenic Diabetes | Phase 2 | Recruiting | Chinese University of Hong Kong | 44 | 2025-04-30 | 2026-04-30 |
| A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer HB-202/HB-201 alternating 2-vector therapy, Placebo, Pembrolizumab - Oropharyngeal Squamous Cell Carcinoma Recurrent | Phase 2 / Phase 3 | Withdrawn | Hookipa Biotech GmbH | 2024-12-01 | 2025-06-22 | |
| Efficacy and Safety of HB-1 for Panic Disorder HB-1, Telmisartan Only Product in Oral Dose Form, Verapamil Only Product in Oral Dose Form - Panic Disorder, Mental Illness | Phase 2 | Terminated | HB BioTech, LLC | 170 | 2024-10-29 | 2026-09-24 |
| First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK Cohort SAT-3247, matched placebo - Duchenne Muscular Dystrophy | Early Phase 1 | Completed | Satellos Bioscience, Inc. | 77 | 2024-08-21 | 2025-05-15 |
| VTP-1000 in Adults With Celiac Disease VTP-1000, Matched Placebo - Celiac Disease | Early Phase 1 | Recruiting | Barinthus Biotherapeutics | 45 | 2024-08-01 | 2026-06-18 |
| A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD). NST-6179 Part A, NST-6179 Part B, Matched Placebo - Intestinal Failure Associated Liver Disease | Phase 2 | Recruiting | NorthSea Therapeutics B.V. | 36 | 2024-01-15 | 2025-01-07 |
| Clinical Efficacy of QYHJ and Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer QingyiHuaji optimized formula, Matched placebo - Pancreatic Neoplasms | Phase 3 | Completed | Fudan University | 305 | 2023-04-17 | 2026-09-03 |
| Melissa Officinalis L. Supplementation for Emotional Health and Sleep Disturbance Lemon Balm Supplement, Matched Placebo - Depression, Anxiety | Not applicable | Completed | Ayub Teaching Hospital | 102 | 2023-01-03 | 2023-05-31 |
| Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia Reparixin, Placebo - Infectious Pneumonia, Severe COVID-19 | Phase 3 | Terminated | Dompé Farmaceutici S.p.A | 414 | 2022-04-27 | 2026-02-24 |
| Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression NV-5138, matched placebo - Treatment Resistant Depression | Phase 2 | Completed | Navitor Pharmaceuticals, Inc. | 250 | 2022-01-18 | 2026-04-17 |
| Low-dose Methotrexate for Change in Global Initiative for Asthma Step 5 Medications in Chronic Severe Asthma Methotrexate, Placebo - Low Dose Methotrexate in Severe Chronic Asthma | Phase 3 | Unknown | University of Catania | 102 | 2021-12-01 | 2021-09-28 |
| CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD CHF5993, CHF1535, Matched placebo - Chronic Obstructive Pulmonary Disease | Phase 4 | Completed | Chiesi Farmaceutici S.p.A. | 106 | 2021-10-28 | 2023-03-24 |
| Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole Lansoprazole, Matched placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Recruiting | Norfolk and Norwich University Hospitals NHS Foundation Trust | 298 | 2021-06-16 | 2025-12-22 |
| Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19 intermediate dose Enoxaparin/ unfractionated heparin, standard prophylactic dose Enoxaparin/ unfractionated heparin, Atorvastatin 20mg - Covid19 | Phase 3 | Completed | Rajaie Cardiovascular Medical and Research Center | 600 | 2020-07-30 | 2021-08-17 |
| Study Investigating the Safety, Tolerability, and PK, PD, of CB-0406 CB-0406 100 mg, CB-0406 200 mg, CB-0406 400 mg - Healthy Volunteers | Phase 1 | Completed | Gilead Sciences | 90 | 2020-07-07 | 2021-06-11 |
| Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers Apo-Hydroxychloroquine, Matched Placebo - Corona Virus Infection | Phase 3 | Withdrawn | St. Joseph's Healthcare Hamilton | 2020-05-01 | 2021-09-27 |
Showing 20 of 72. Sign in to see all of them.
Alcoholism (3) · Asthma (3) · Gastroesophageal Reflux (3) · Idiopathic Pulmonary Fibrosis (3) · Anxiety Disorders (2) · COVID-19 (2) · Cocaine-Related Disorders (2) · Colitis, Ulcerative (2) · Cystic Fibrosis (2) · Depression (2) · Head and Neck Neoplasms (2) · Hyperphagia (2) · Influenza, Human (2) · Marijuana Abuse (2) · Muscular Dystrophy, Duchenne (2)
New York State Psychiatric Institute (3) · University of California, Los Angeles (3) · GlaxoSmithKline (2) · Inotrem (2) · Khon Kaen University (2) · Montefiore Medical Center (2) · Reckitt Benckiser Healthcare (UK) Limited (2) · University College, London (2) · Vertex Pharmaceuticals Incorporated (2) · ASLAN Pharmaceuticals (1) · Abbott (1) · AstraZeneca (1) · Ayub Teaching Hospital (1) · Barinthus Biotherapeutics (1) · Beijing Tongren Hospital (1)
United States (34) · United Kingdom (12) · Australia (9) · Spain (6) · Belgium (5) · Canada (5) · China (5) · Germany (4) · Thailand (4) · Argentina (3) · France (3) · Italy (3) · Turkey (Türkiye) (3) · Austria (2) · Denmark (2)
Eric Hollander, MD (3) · Lara Ray, PhD (2) · Aiguang Zhao (1) · Aldiouma Diallo, MD (1) · Amit Assa, MD (1) · Andre M Tapp, MD (1) · Ardis A Moe, M.D. (1) · Behnood Bikdeli, MD, MS (1) · Brian H Annex, MD (1) · Charles Craddock (1) · Charles H. Kellner, M.D. (1) · Chris Brett, MD (1) · Claire M Williams, PhD (1) · Elaine Watkins, DO, MSPH (1)
PMID 21473764, PMID 22207903, PMID 24070431, PMID 24684534, PMID 24775991, PMID 24911028, PMID 25070546, PMID 25209738, PMID 25523634, PMID 25565885, PMID 27746224, PMID 29794557, PMID 29885068, PMID 30277655, PMID 30334692, PMID 31887169, PMID 32992075, PMID 33331662, PMID 33710614, PMID 33734299, PMID 34233965, PMID 34996756, PMID 35165110, PMID 35244208, PMID 36102596, PMID 36944357, PMID 36951472, PMID 37269870, PMID 37927585, PMID 37983082, PMID 39402448, PMID 39420338, PMID 39909521, PMID 40028879, PMID 40656115, PMID 40825084
2018 (2), U54DA037842 (2), 2009 (1), 2016 (1), 2017 (1), 2023 (1), R01DA031826 (1), R21AA022214 (1), R21AT000939 (1), U10DA013732 (1)